SEO URLwww.firestrike.ai/deals/dianthus-therapeutics-braidwell-acquisition-2026
acquisitionAnnounced · Mar 15, 2026biotechnologySource · Unverified ReportsArticle · Factual
Braidwell acquires Dianthus Therapeutics
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$32.9M
Target
Dianthus Therapeutics
NASDAQ: DNTH · New York City, New York
Acquirer
Braidwell
Financial Stake
Status
Completed
Braidwell agreed to acquire Dianthus Therapeutics. Reported deal value: $32.9M. Status: Completed. Sector: biotechnology. Target headquarters context: New York City, New York, United States.
This page summarizes publicly available information about the transaction as of 2026-03-15. Figures and status may change as filings and press coverage update.
Braidwell LP , an investment management firm, has acquired a new stake of 835,057 shares in Dianthus Therapeutics , Inc. , a clinical-stage biotechnology company developing complement therapeutics
Deal timeline
Announced
Mar 15, 2026 · nationaltoday.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biotechnology with a reported deal value of $32.9M. Figures and status may change as sources update.
Sources: nationaltoday.com · Primary article · FireStrike proprietary index